What happened
Merck has agreed to a research collaboration with Isomorphic Labs, a company that applies artificial intelligence to drug design, with the aim of identifying small molecule candidates against a cancer target, STAT reported. The specific target has not been disclosed, although it was characterized as being of strategic importance.
Under the arrangement, Isomorphic will contribute its in-house drug design engine, which will be combined with wet lab data that Merck has already generated. Merck will take responsibility for preclinical and clinical development of any resulting products and will also handle their manufacturing and commercialization.
Context
Isomorphic Labs relies on Nobel-winning technology capable of modeling the way molecules attach to proteins. The Merck agreement is not a first for the company. It follows other collaborations Isomorphic has struck with large pharmaceutical groups, placing Merck among several major drugmakers that have chosen to work with it.
O briefing
A semana em tecnologia, em um só e-mail.
As reportagens que valem o seu tempo, toda semana. Cancele quando quiser.
